{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T16:31:13Z","timestamp":1694968273275},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2334-12-377","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T06:14:44Z","timestamp":1356588884000},"source":"Crossref","is-referenced-by-count":2,"title":["The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil"],"prefix":"10.1186","volume":"12","author":[{"given":"Simara","family":"Artico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine Medeiros","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice Beatriz Treter","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Dornelles","family":"Picon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,27]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-a, non-B viral hepatitis genome. Science. 1989, 244: 359-362. 10.1126\/science.2523562.","journal-title":"Science"},{"key":"2176_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1089-3261(05)70321-4","volume":"1","author":"MJ Alter","year":"1997","unstructured":"Alter MJ: The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997, 1: 559-568. 10.1016\/S1089-3261(05)70321-4. vi-vii","journal-title":"Clin Liver Dis"},{"key":"2176_CR3","unstructured":"Relat\u00f3rio do Grupo de Estudos da Sociedade Brasileira de Hepatologia: Epidemiologia da infec\u00e7\u00e3o pelo v\u00edrus da hepatite C no Brasil. [\n                    http:\/\/www.sbhepatologia.org.br\n                    \n                  ]"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med. 2001, 345: 41-52. 10.1056\/NEJM200107053450107.","journal-title":"N Engl J Med"},{"key":"2176_CR5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","volume":"321","author":"GL Davis","year":"1989","unstructured":"Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis interventional therapy group. N Engl J Med. 1989, 321: 1501-1506. 10.1056\/NEJM198911303212203.","journal-title":"N Engl J Med"},{"key":"2176_CR6","doi-asserted-by":"publisher","first-page":"83S","DOI":"10.1002\/hep.510260715","volume":"26","author":"RL Carithers Jr","year":"1997","unstructured":"Carithers RL, Emerson SS: Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997, 26: 83S-88S. 10.1002\/hep.510260715.","journal-title":"Hepatology"},{"key":"2176_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","volume":"127","author":"P Marcellin","year":"1997","unstructured":"Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, et al: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997, 127: 875-881.","journal-title":"Ann Intern Med"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"101S","DOI":"10.1002\/hep.510260718","volume":"26","author":"EB Keeffe","year":"1997","unstructured":"Keeffe EB, Hollinger FB: Therapy of hepatitis C: consensus interferon trials. Consensus interferon study group. Hepatology. 1997, 26: 101S-107S. 10.1002\/hep.510260718.","journal-title":"Hepatology"},{"key":"2176_CR9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med. 1998, 339: 1485-1492. 10.1056\/NEJM199811193392101.","journal-title":"N Engl J Med"},{"key":"2176_CR10","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","volume":"352","author":"T Poynard","year":"1998","unstructured":"Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group (IHIT). Lancet. 1998, 352: 1426-1432. 10.1016\/S0140-6736(98)07124-4.","journal-title":"Lancet"},{"key":"2176_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","volume":"339","author":"GL Davis","year":"1998","unstructured":"Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International hepatitis interventional therapy group. N Engl J Med. 1998, 339: 1493-1499. 10.1056\/NEJM199811193392102.","journal-title":"N Engl J Med"},{"key":"2176_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","volume":"20","author":"GR Foster","year":"2004","unstructured":"Foster GR: Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004, 20: 825-830. 10.1111\/j.1365-2036.2004.02170.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"2176_CR13","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S Zeuzem","year":"2000","unstructured":"Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, et al: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000, 343: 1666-1672. 10.1056\/NEJM200012073432301.","journal-title":"N Engl J Med"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1053\/jhep.2001.26371","volume":"34","author":"KL Lindsay","year":"2001","unstructured":"Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001, 34: 395-403.","journal-title":"Hepatology"},{"key":"2176_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056\/NEJMoa020047.","journal-title":"N Engl J Med"},{"key":"2176_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-965. 10.1016\/S0140-6736(01)06102-5.","journal-title":"Lancet"},{"key":"2176_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004, 140: 346-355.","journal-title":"Ann Intern Med"},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM199903113401001","volume":"340","author":"HB El-Serag","year":"1999","unstructured":"El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the united states. N Engl J Med. 1999, 340: 745-750. 10.1056\/NEJM199903113401001.","journal-title":"N Engl J Med"},{"key":"2176_CR19","first-page":"S3","volume":"36","author":"National Institutes of Health Consensus Development Conference Statement","year":"2002","unstructured":"National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002\u2013june 10\u201312, 2002. Hepatology. 2002, 36: S3-20.","journal-title":"Hepatology"},{"key":"2176_CR20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0168-8278(99)80154-8","volume":"30","author":"EASL International","year":"1999","unstructured":"International EASL: Consensus conference on hepatitis C. Paris, 26\u201328, february 1999, consensus statement. European association for the study of the liver. J Hepatol. 1999, 30: 956-961.","journal-title":"J Hepatol"},{"key":"2176_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","volume":"126","author":"ML Shiffman","year":"2004","unstructured":"Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, et al: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004, 126: 1015-1023. 10.1053\/j.gastro.2004.01.014. discussion 1947","journal-title":"Gastroenterology"},{"key":"2176_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4321\/S1130-01082005000500002","volume":"97","author":"F Carnicer","year":"2005","unstructured":"Carnicer F, Zapater P, Gutierrez A, Garcia A, Ruiz F, Lopez M: Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin. Rev Esp Enferm Dig. 2005, 97: 306-316.","journal-title":"Rev Esp Enferm Dig"},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1590\/S1413-86702006000100003","volume":"10","author":"E Parise","year":"2006","unstructured":"Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, et al: Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis. 2006, 10: 11-16. 10.1590\/S1413-86702006000100003.","journal-title":"Braz J Infect Dis"},{"key":"2176_CR24","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1002\/hep.1840360717","volume":"36","author":"ML Shiffman","year":"2002","unstructured":"Shiffman ML: Retreatment of patients with chronic hepatitis C. Hepatology. 2002, 36: S128-134.","journal-title":"Hepatology"},{"key":"2176_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jhep.2005.03.015","volume":"43","author":"EL Krawitt","year":"2005","unstructured":"Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD: Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol. 2005, 43: 243-249. 10.1016\/j.jhep.2005.03.015.","journal-title":"J Hepatol"},{"key":"2176_CR26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1053\/j.gastro.2006.02.016","volume":"130","author":"G Taliani","year":"2006","unstructured":"Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, et al: Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. 2006, 130: 1098-1106. 10.1053\/j.gastro.2006.02.016.","journal-title":"Gastroenterology"},{"key":"2176_CR27","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1007\/s10620-006-9192-3","volume":"51","author":"A Mathew","year":"2006","unstructured":"Mathew A, Peiffer LP, Rhoades K, McGarrity T: Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci. 2006, 51: 1956-1961. 10.1007\/s10620-006-9192-3.","journal-title":"Dig Dis Sci"},{"key":"2176_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10620-005-2563-3","volume":"50","author":"SK Herrine","year":"2005","unstructured":"Herrine SK, Brown RS, Bernstein DE, Ondovik MS, Lentz E, Te H: Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci. 2005, 50: 719-726. 10.1007\/s10620-005-2563-3.","journal-title":"Dig Dis Sci"},{"key":"2176_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1471-2334-10-212","volume":"10","author":"FL Goncales Jr","year":"2010","unstructured":"Goncales FL, Moma CA, Vigani AG, Angerami AF, Goncales ES, Tozzo R, Pavan MH, Goncales NS: Retreatment of hepatitis C patients with Pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?. BMC Infect Dis. 2010, 10: 212-10.1186\/1471-2334-10-212.","journal-title":"BMC Infect Dis"},{"key":"2176_CR30","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/gut.2005.083113","volume":"55","author":"M Sherman","year":"2006","unstructured":"Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS: Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut. 2006, 55: 1631-1638. 10.1136\/gut.2005.083113.","journal-title":"Gut"},{"key":"2176_CR31","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/gut.51.6.864","volume":"51","author":"C Camma","year":"2002","unstructured":"Camma C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, Mangia A, Andriulli A, Puoti M, Spadaro A, et al: Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut. 2002, 51: 864-869. 10.1136\/gut.51.6.864.","journal-title":"Gut"},{"key":"2176_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.dld.2006.08.007","volume":"39","author":"M Basso","year":"2007","unstructured":"Basso M, Torre F, Grasso A, Percario G, Azzola E, Artioli S, Blanchi S, Pelli N, Picciotto A: Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Liver Dis. 2007, 39: 47-51. 10.1016\/j.dld.2006.08.007.","journal-title":"Dig Liver Dis"},{"key":"2176_CR33","first-page":"431","volume-title":"In Protocolos cl\u00ednicos e diretrizes terap\u00eauticas \u2013 medicamentos excepcionais","author":"GB Sander","year":"2002","unstructured":"Sander GB, Kuchenbecker RS, Amaral KM, Krug BC, Picon PD: Hepatite Viral Cr\u00f4nica C. In Protocolos cl\u00ednicos e diretrizes terap\u00eauticas \u2013 medicamentos excepcionais. Edited by: Picon PD, Beltrame A. 2002, Porto Alegre: Gr\u00e1fica Palotti, 431-454."},{"key":"2176_CR34","volume-title":"In Book Portaria n\u00ba 34, de 28 de setembro de 2007. Disp\u00f5e sobre Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite Viral Cr\u00f4nica C","author":"M da Sa\u00fade","year":"2007","unstructured":"da Sa\u00fade M: Portaria n\u00ba 34, de 28 de setembro de 2007. Disp\u00f5e sobre Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite Viral Cr\u00f4nica C. In Book Portaria n\u00ba 34, de 28 de setembro de 2007. Disp\u00f5e sobre Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite Viral Cr\u00f4nica C. 2007, City: Di\u00e1rio Oficial da Uni\u00e3o, Poder Executivo"},{"key":"2176_CR35","first-page":"19","volume":"87","author":"KM Amaral","year":"2006","unstructured":"Amaral KM, Reis JG, Picon PD: Aten\u00e7\u00e3o farmac\u00eautica no sistema \u00fanico de sa\u00fade: um exemplo de experi\u00eancia bem sucedida com pacientes portadores de hepatite C. Rev Bras Farm. 2006, 87: 19-21.","journal-title":"Rev Bras Farm"},{"key":"2176_CR36","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.1002\/hep.1840360729","volume":"36","author":"DB Strader","year":"2002","unstructured":"Strader DB: Understudied populations with hepatitis C. Hepatology. 2002, 36: S226-236.","journal-title":"Hepatology"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-12-377\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:45:37Z","timestamp":1548204337000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-12-377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-12-377","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"article-number":"377"}}